Literature DB >> 21416472

High-risk stage II colon cancer after curative resection.

Harunobu Sato1, Koutarou Maeda, Kenichi Sugihara, Hidetaka Mochizuki, Kenjiro Kotake, Tetsuo Teramoto, Shingo Kameoka, Yukio Saito, Keiichi Takahashi, Takashi Hirai, Masayuki Ohue, Kazuo Shirouzu, Yoshiharu Sakai, Toshiaki Watanabe, Koichi Hirata, Katsuyoshi Hatakeyama.   

Abstract

OBJECTIVES: This study was designed to clarify which attributes of stage II colon cancer are associated with tumor recurrence and survival after curative resection, and the effects of adjuvant chemotherapy (ACT).
METHODS: We retrospectively reviewed outcomes and clinicopathological characteristics of 1476 patients with stage II colon cancer who underwent curative resection.
RESULTS: Of 1476 patients, 204 (13.8%) developed recurrence. Macroscopic type, serum CA19-9 levels, venous invasion, emergency operation, and postoperative ileus were independently associated with overall recurrence. Carbohydrate antigen (CA)19-9 levels, the number of dissected lymph nodes (LN), sex, age, ACT, emergency operation, venous invasion, and macroscopic type were independently associated with poor prognosis. Prognosis was significantly better in patients who received ACT than in those who did not. Among patients with extensive venous invasion, those with fewer than 13 dissected LNs, male patients, and patients >50 years old, the prognosis was significantly better in patients who received ACT than in those who did not.
CONCLUSIONS: ACT for stage II colon cancer is recommended to improve the prognosis of patients with extensive venous invasion, patients with fewer than 13 dissected LNs, patients >50 years old, and male patients, particularly patients with more than two of these risk factors.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21416472     DOI: 10.1002/jso.21914

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

1.  Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer.

Authors:  Yifan Peng; Lin Wang; Jin Gu
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

2.  High-risk Stage II Colorectal Cancers Carry an Equivalent Risk of Peritoneal Recurrence to Stage III.

Authors:  Hiroaki Nozawa; Kazushige Kawai; Keisuke Hata; Toshiaki Tanaka; Takeshi Nishikawa; Kensuke Otani; Kazuhito Sasaki; Manabu Kaneko; Shigenobu Emoto; Koji Murono
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 3.  Stage migration vs immunology: The lymph node count story in colon cancer.

Authors:  Bruno Märkl
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

4.  Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer.

Authors:  Kosuke Mima; Junji Kurashige; Nobutomo Miyanari; Atsushi Morito; Shinsei Yumoto; Takashi Matsumoto; Keisuke Kosumi; Mitsuhiro Inoue; Takao Mizumoto; Tatsuo Kubota; Hideo Baba
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage II/III colon cancer.

Authors:  Hironori Mizuno; Hideo Miyake; Hidemasa Nagai; Yuichiro Yoshioka; Koji Shibata; Soichiro Asai; Junichi Takamizawa; Norihiro Yuasa
Journal:  Langenbecks Arch Surg       Date:  2021-06-19       Impact factor: 3.445

6.  Colorectal cancer in northwestern iran.

Authors:  Rahim Mahmodlou; Payvand Mohammadi; Nariman Sepehrvand
Journal:  ISRN Gastroenterol       Date:  2012-06-12

7.  Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence.

Authors:  Takuzo Hashimoto; Michio Itabashi; Shinpei Ogawa; Tomoichiro Hirosawa; Yoshiko Bamba; Satoru Shimizu; Shingo Kameoka
Journal:  Surg Today       Date:  2013-12-21       Impact factor: 2.549

8.  Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis.

Authors:  Roberta Grande; Domenico Corsi; Raffaello Mancini; Donatello Gemma; Fabrizio Ciancola; Isabella Sperduti; Lorena Rossi; Agnese Fabbri; Maria G Diodoro; Enzo Ruggeri; Germano Zampa; Sara Bianchetti; Teresa Gamucci
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

9.  Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution.

Authors:  Keizo Yamaguchi; Yutaka Ogata; Yoshito Akagi; Kazuo Shirouzu
Journal:  Oncol Lett       Date:  2013-07-01       Impact factor: 2.967

10.  Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer.

Authors:  Yoshito Akagi; Kazuo Shirouzu; Tetsushi Kinugasa
Journal:  J Surg Oncol       Date:  2013-08-23       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.